Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.

@article{Byington2006ImpactOT,
  title={Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.},
  author={Carrie L. Byington and Kent Korgenski and Judy A. Daly and Krow K Ampofo and Andrew T. Pavia and Edward O. Mason},
  journal={The Pediatric infectious disease journal},
  year={2006},
  volume={25 3},
  pages={250-4}
}
BACKGROUND Pediatric pneumococcal parapneumonic empyema (PPE) has become increasingly common. In the last decade, Utah has had one of the highest rates of PPE in the United States, 14/100,000 children, attributed primarily to Streptococcus pneumoniae serotype 1. Our objective was to describe the temporal trends in PPE in Utah before and after the availability of the 7-valent pneumococcal conjugate vaccine (PCV-7). METHODS The Intermountain Health Care (IHC) data warehouse was queried for all… CONTINUE READING